Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous

Nadia Bouzidi1,2, Habib Gamra3,4

  • 1Cardiothrombosis Research Laboratory, LR12SP16 University of Monastir, Monastir, 5000, Tunisia. nadiabouzidi1@outlook.fr.

PubMed

Insights

Interleukin-6 (IL-6) levels correlate with coronary artery disease (CAD) severity, as measured by the Gensini score. Elevated IL-6 may serve as a marker for evaluating myocardial necrosis in patients with myocardial infarction.

Area of Science:

  • Cardiology
  • Immunology
  • Biomarkers

Background:

  • Cytokines, including interleukin-6 (IL-6), are implicated in atherosclerosis.
  • The relationship between IL-6 and coronary artery disease (CAD) severity requires further investigation.

Purpose of the Study:

  • To examine the association between IL-6 levels and the angiographic severity of CAD.
  • To evaluate IL-6 as a potential predictor of myocardial infarct size.

Main Methods:

  • A study involving 310 CAD patients and 210 controls.
  • CAD severity assessed using Gensini score (GS), stenosis degree, and vessel count.
  • Patients stratified into high (≥9.5 pg/mL) and low (<9.5 pg/mL) IL-6 groups.

Main Results:

  • IL-6 levels were significantly higher in CAD patients than controls.
  • High IL-6 levels correlated with higher GS (p=0.027) but not stenosis degree or vessel score.
  • ROC analysis indicated IL-6 is a powerful predictor of infarct size in myocardial infarction patients (AUC: 0.941).

Conclusions:

  • IL-6 levels are associated with CAD severity, particularly when assessed by GS.
  • IL-6 shows potential as a valuable biomarker for assessing myocardial necrosis, especially in STEMI patients.
Abstract